Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):1924–1926. doi: 10.1128/aac.37.9.1924

Evaluation of a novel fluorescence polarization immunoassay for teicoplanin.

H Cox 1, M Whitby 1, G Nimmo 1, G Williams 1
PMCID: PMC188093  PMID: 8239606

Abstract

A fluorescence polarization immunoassay (FPI) for teicoplanin that uses the TDx Instrument System (Abbott, Irving, Tex.) as an automated analyzer has been developed by Innotron of Oregon Inc. and was evaluated in patients with staphylococcal infections enrolled in a clinical trial of the antibiotic. The assay proved accurate in estimating concentrations of between 5 and 100 mg/liter. The intraassay coefficient of variation was < 7.3%, while the interassay variance was < 11.6% against three commercially prepared standards at known concentrations of approximately 5, 35, and 75 mg/liter. Against routinely prepared standards at 10 concentrations between 5 and 100 mg/liter analyzed in a single run, the coefficient of variance did not exceed 4.3%. Compared with bioassay, the FPI demonstrated good correlation in terms of reliability (r = 0.909) in samples containing teicoplanin only and specificity (r = 0.916) in samples containing both teicoplanin and gentamicin. With a turnaround time of 20 min and with only 50 microliters of serum needed for estimation of the amount of drug in a sample, the FPI described here should provide a useful method of teicoplanin measurement in routine diagnostic laboratories.

Full text

PDF
1924

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Del Favero A., Menichetti F., Guerciolini R., Bucaneve G., Baldelli F., Aversa F., Terenzi A., Davis S., Pauluzzi S. Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients. Antimicrob Agents Chemother. 1987 Jul;31(7):1126–1129. doi: 10.1128/aac.31.7.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Erickson R. C., Hildebrand A. R., Hoffman P. F., Gibson C. B. A sensitive bioassay for teicoplanin in serum in the presence or absence of other antibiotics. Diagn Microbiol Infect Dis. 1989 May-Jun;12(3):235–241. doi: 10.1016/0732-8893(89)90020-5. [DOI] [PubMed] [Google Scholar]
  3. Patton K. R., Beg A., Felmingham D., Ridgway G. L., Grüneberg R. N. Determination of teicoplanin concentration in serum using a bioassay technique. Drugs Exp Clin Res. 1987;13(9):547–550. [PubMed] [Google Scholar]
  4. Rybak M. J., Bailey E. M., Reddy V. N. Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrob Agents Chemother. 1991 Aug;35(8):1586–1590. doi: 10.1128/aac.35.8.1586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Rybak M. J., Lerner S. A., Levine D. P., Albrecht L. M., McNeil P. L., Thompson G. A., Kenny M. T., Yuh L. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother. 1991 Apr;35(4):696–700. doi: 10.1128/aac.35.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Stevens P., Young L. S. Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother. 1977 Aug;12(2):286–287. doi: 10.1128/aac.12.2.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Van der Auwera P., Aoun M., Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother. 1991 Mar;35(3):451–457. doi: 10.1128/aac.35.3.451. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES